Drug Description in Trials / DrugBank / KEGG DRUG

Search results

No.

Drug (Description in trials)

DrugBank

KEGG DRUG

KEGG GENES

KEGG PATHWAY

Disease ID

1

[1] Exenatide (Byetta)

[1] Exenatide (Byetta (TN)) 💬

[1] GLP1R 💬

[3] Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬

[3] 6, 78, 193 💬

2

Byetta 5 micrograms

[1] Exenatide (Byetta)

[1] Exenatide (Byetta (TN)) 💬

[1] GLP1R 💬

[3] Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬

[1] 6 💬

3

Exenatide
(Byetta (TN))

[1] Exenatide (Byetta)

[1] Exenatide (Byetta (TN)) 💬

[1] GLP1R 💬

[3] Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬

[6] 6, 17, 72, 78, 193, 233 💬

4

Exenatide 10 micrograms
(Byetta (TN))

[1] Exenatide (Byetta)

[1] Exenatide (Byetta (TN)) 💬

[1] GLP1R 💬

[3] Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬

[1] 6 💬

5

Exenatide 5 micrograms
(Byetta (TN))

[1] Exenatide (Byetta)

[1] Exenatide (Byetta (TN)) 💬

[1] GLP1R 💬

[3] Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬

[1] 6 💬

6

Exenatide extended release 2mg (Bydureon)
(Byetta (TN))

[1] Exenatide (Byetta)

[1] Exenatide (Byetta (TN)) 💬

[1] GLP1R 💬

[3] Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬

[1] 6 💬

7

Exenatide Pen Injector [Bydureon]
(Byetta (TN))

[1] Exenatide (Byetta)

[1] Exenatide (Byetta (TN)) 💬

[1] GLP1R 💬

[3] Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬

[1] 17 💬

8

Experimental: GLP1-RA (exenatide) administration
(Byetta (TN))

[1] Exenatide (Byetta)

[1] Exenatide (Byetta (TN)) 💬

[1] GLP1R 💬

[3] Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬

[2] 72, 78 💬